A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
Key claim: IOA-244, a selective PI3Kδ inhibitor, is being evaluated for safety and anti-tumour immune response as monotherapy and in combination with ruxolitinib in patients with Primary Myelofibrosis.
Abstract
The objective of study IOA-244-101 is to determine whether IOA-244 is safe and tolerable in cancer patients (Part A). In addition, the study will assess whether IOA-244 can increase the anti-tumour immune response in patients both as monotherapy and in combination pemetrexed/cisplatin/avelumab (Part B Mesothelioma and NSCLC 1st line), in combination with avelumab (Part B Cutaneous Melanoma and NSCLC 2nd/3rd line) and ruxolitinib (Part B Primary Myelofibrosis)
Why this matters
PMF remains the MPN subtype with the highest mortality and the greatest unmet need for therapies that move beyond JAK inhibition alone. The IOA-244 trial is the second selective PI3Kδ inhibitor (after roginolisib) to be tested in combination with ruxolitinib in PMF, suggesting PI3K-AKT co-inhibition is consolidating as a distinct combinatorial axis for the JAKi-refractory/suboptimal PMF subpopulation. Tracking this on the PMF page keeps the subtype-specific picture of emerging non-JAK targets coherent.